FDA’s Opioid Guidance: Industry Celebrates Multi-Tiered Labeling Cake
Executive Summary
Endo says label differentiation in the guidance is a positive step; Commissioner Hamburg tells Congress that if new opioid formulations “significantly” deter abuse, generic versions will have to as well.
You may also be interested in...
Keeping Track: Opdivo Dosing Simplified; Yosprala, Cuvitru Approved; Telotristat Review Lengthened
The latest drug development news and highlights from our FDA Performance Tracker.
Pfizer’s Embeda Joins Abuse-Deterrent Club, But FDA Wants Assurances
As with Purdue’s Targiniq, agency requires a post-marketing study to determine whether the new morphine/naltrexone formulation actually deters abuse.
Can FDA Finally Put Its Zohydro Problem Behind It?
FDA sees progress on the opioid front with Zogenix and Teva the latest to seek abuse-deterrence claims, but is the existing science able to adequately fight abuse?